This would also be expected for patients with HER2 overexpressing BC, but with current treatment regimens, employing the dual HER2 blockades, an improvement has been observed in disease‐free survival as well as an increase in survival rates following the diagnosis of CNS metastasis among HER2 BC patients.28 This evidence concerns the gene ERBB2 and breast cancer.